Stocks and Investing
Stocks and Investing
Thu, April 23, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Difei Yang Maintained (XERS) at Strong Buy with Decreased Target to $14 on, Apr 23rd, 2020
Difei Yang of Mizuho, Maintained "Xeris Biopharma Holdings, Inc." (XERS) at Strong Buy with Decreased Target from $18 to $14 on, Apr 23rd, 2020.
Difei has made no other calls on XERS in the last 4 months.
There is 1 other peer that has a rating on XERS. Out of the 1 peers that are also analyzing XERS, 0 agree with Difei's Rating of Hold.
This is the rating of the analyst that currently disagrees with Difei
- David Amsellem of "Piper Sandler" Initiated at Buy and Held Target at $12 on, Tuesday, February 18th, 2020